glp-1 study finds GLP-1s may lower long-term employer health costs GLP-1 Receptor Agonists as Treatments

Both of these options are not quick fixes and require a long-term commitment, so it is best to have as much information as possible before deciding if either option is right for you

Int J Life Sci Pharma Res 2015

Theres a newer peptide called PDA, or pentadeca arginate, that has a very similar molecular structure as BPC-157, but instead of it being an acetate, its an arginate essentially just swapping out one amino acid for another

Some patients recover faster

References: (1) Wax B, et al

Of those 10 patients with oral exposures, most ( n = 5, 50%) resulted from inadvertently taking a double dose and only 1 (10%) patient manifested symptoms (fatigue and nausea)